+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of the drug NNC0487-0111 in adults with excess body weight and moderate-to-severe obstructive sleep apnoea OSA who are not treated with positive airway pressure. This Phase 3 study randomizes participants to receive either NNC0487-0111 or a placebo to assess their ability to lose weight and improve sleep apnoea symptoms. Participants will receive weekly injections under the skin using pre-filled pen-injectors of either NNC0487-0111 or placebo. Both groups will follow a reduced-calorie diet and increase physical activity. The treatment period lasts 80 weeks, during which the effects on body weight and sleep apnoea will be monitored. During the study, participants will have regular assessments including measurements of body weight, apnoea-hypopnoea index AHI, sleepiness scales, blood pressure, cholesterol levels, blood sugar, and other health indicators. Safety will be monitored through tracking adverse events up to 84 weeks. The study aims to measure changes from baseline to week 80 to evaluate treatment impact.

Age: 18Years +All GendersPhase 3
80 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of a medicine called NNC0487-0111 in adults with overweight or obesity who also have moderate-to-severe obstructive sleep apnoea OSA treated with positive airway pressure. This Phase 3 study compares NNC0487-0111 to a placebo to see how well it helps reduce body weight and improve sleep apnoea symptoms over time. Participants will be randomly assigned to receive one of these treatments, which are injected under the skin weekly. Participants will receive either one of two dose levels of NNC0487-0111 or a matching placebo injection once a week. Both groups will also follow a reduced-calorie diet and increase physical activity as part of the study. The injections are given using pre-filled pen-injectors at areas such as the thigh, abdomen, or upper arm. The treatment period lasts up to 80 weeks, during which body weight and sleep apnoea severity are closely monitored. Throughout the study, participants will have regular assessments to measure changes in body weight, apnoea-hypopnoea index AHI, sleep quality, blood pressure, blood sugar, cholesterol, and other health markers. Safety is monitored by tracking adverse events until week 84. The study also evaluates improvements in sleep-related symptoms and the potential to reduce or stop positive airway pressure therapy. Total participation may last up to 84 weeks, including follow-up for safety and health outcomes.

Age: 18Years +All GendersPhase 3
92 locations
P

Actively Recruiting

Researchers are testing a new medicine called SNV1521 for people with advanced or metastatic solid tumors. The study aims to find out if SNV1521 is safe, well-tolerated, and effective in treating these cancers. This phase 1 trial also explores different doses of SNV1521 to determine the most effective and safe dosage, as well as its potential use in combination with other cancer therapies. Participants will receive SNV1521 as an oral tablet with the dose and frequency depending on the treatment group. The study includes several experimental arms such as monotherapy dose escalation and expansion, combination dose escalation, and specific dose expansions for various cancers including prostate, pancreatic, breast, ovarian, and solid tumors with brain metastases. Other drugs like DB-1310 infusion, Abiraterone, and Darolutamide oral are also involved depending on the treatment arm. During the study, participants will be monitored closely for safety and tolerability, including checking for dose-limiting toxicities during the first 28-day treatment cycle and ongoing safety assessments up to 13 months from the first dose. Researchers will evaluate disease status using measurable criteria and assess overall health and performance status. The trial runs through December 2027, with participants undergoing regular evaluations to measure the effects and side effects of the treatments.

Age: 18Years +All GendersPhase 1
25 locations